Table 1_Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.docx
<p>Endometrial cancer (EC) is one of the most common gynecologic malignancies with increasing morbidity. The prognosis for patients diagnosed with early-stage EC remains favorable; however, for patients with recurrent or metastatic EC, the prognosis is poor and treatment options, until recentl...
Saved in:
| Main Author: | Hu Feng (6641357) (author) |
|---|---|
| Other Authors: | Shasha Bi (19675897) (author), Shanshan Sun (275585) (author), Hongbo Yang (267562) (author), Haoxing Zhou (19675900) (author), Jingjing Mao (175629) (author), Na Li (6550) (author), Fujun Yang (8151096) (author) |
| Published: |
2024
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Table 2_Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.docx
by: Hu Feng (6641357)
Published: (2024) -
Image 1_Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.jpeg
by: Hu Feng (6641357)
Published: (2024) -
Image 4_Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.jpeg
by: Hu Feng (6641357)
Published: (2024) -
Image 3_Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.jpeg
by: Hu Feng (6641357)
Published: (2024) -
Image 2_Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.jpeg
by: Hu Feng (6641357)
Published: (2024)